If needle aversion is the primary barrier to semaglutide, the oral formulation removes that obstacle
Patients should be seen or contacted within 2-4 weeks of initiation to assess tolerability, review lifestyle adherence, and address concerns
Metabolic secondary outcomes included HbA1c, blood pressure (systolic and diastolic), HR, total cholesterol, triglycerides, hsCRP, HbA1c in participants with pre-existing pre-diabetes and T2D, blood pressure in participants with pre-existing hypertension and changes in T2D, and hypertension medication used in participants with T2D and hypertension, respectively
Professional guidelines from organizations such as the American Gastroenterological Association and the Endocrine Society recommend that weight management treatment, including pharmacotherapy, be provided within the context of ongoing clinical care with regular monitoring